Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors

Journal of Clinical Oncology

Volumn 27, Issue 27, 2009, Pages 4599-4604

  Furman, Wayne L ^a   Navid, Fariba ^a   Daw, Najat C ^a   Beth McCarville, M ^a   McGregor, Lisa M ^a   Spunt, Sheri L ^a   Rodriguez Galindo, Carlos ^a   Panetta, John C ^a   Crews, Kristine R ^a   Wu, Jianrong ^a   Gajjar, Amar J ^a   Houghton, Peter J ^a   Santana, Victor M ^a   Stewart, Clinton F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CEFIXIME; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; IRINOTECAN; PROTEIN TYROSINE KINASE INHIBITOR;

ADOLESCENT; ADRENAL CORTEX CARCINOMA; ADULT; ARTICLE; BRAIN TUMOR; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EXPOSURE; DRUG TOLERANCE; EWING SARCOMA; FEMALE; HEPATOBLASTOMA; HUMAN; INFANT; LIVER CELL CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEPHROBLASTOMA; NEUROBLASTOMA; OSTEOSARCOMA; PEDIATRICS; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE DRUG DOSE; SOLID TUMOR; TREATMENT DURATION; TREATMENT RESPONSE; UNDIFFERENTIATED CARCINOMA;

ADMINISTRATION, ORAL; ADOLESCENT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; DRUG SYNERGISM; FEMALE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; TOXICITY TESTS; YOUNG ADULT;

EID: 76749168084     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.6642     Document Type: Article

References (29)

1. Rothenberg ML, Kuhn JG, Burris HA3, et al: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204, 1993
2. Furman WL, Stewart CF, Poquette CA, et al: Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17:1815-1824, 1999
3. Cosetti M, Wexler LH, Calleja E, et al: Irinotecan for pediatric solid tumors: The Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol 24: 101-105, 2002
4. Bisogno G, Riccardi R, Ruggiero A, et al: Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer 106:703-707, 2006
5. Pappo AS, Lyden E, Breitfeld P, et al: Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol 25:362-369, 2007
6. Osone S, Hosoi H, Tsuchiya K, et al: Lowdose protracted irinotecan as a palliative chemotherapy for advanced neuroblastoma. J Pediatr Hematol Oncol 30:853-856, 2008
7. Koizumi F, Kanzawa F, Ueda Y, et al: Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 108:464-472, 2004
8. Stewart CF, Leggas M, Schuetz JD, et al: Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64:7491-7499, 2004
9. Furman WL, Crews KR, Billups C, et al: Ce-fixime allows greater dose escalation of oral irinotecan: A phase I study in pediatric patients with refractory solid tumors. J Clin Oncol 24:563-570, 2006
10. Soepenberg O, Dumez H, Verweij J, et al: Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin Cancer Res 11:1504-1511, 2005
11. Kuppens IE, Dansin E, Boot H, et al: Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. Clin Cancer Res 12:3774-3781, 2006
12. Schoemaker NE, Kuppens IE, Huinink WW, et al: Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours. Cancer Chemother Pharmacol 55:263-270, 2005
13. Drengler RL, Kuhn JG, Schaaf LJ, et al: Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 17:685-696, 1999
14. Pitot HC, Adjei AA, Reid JM, et al: A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors. Cancer Chemother Pharmacol 58:165-172, 2006
15. Kuppens IE, Witteveen EO, Jewell RC, et al: A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res 13: 3276-3285, 2007
16. Fracasso PM, Goldstein LJ, de Alwis DP, et al: Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res 10:7220-7228, 2004
17. Breedveld P, Beijnen JH, Schellens JH: Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 27:17-24, 2006
18. Kuppens IE, Breedveld P, Beijnen JH, et al: Modulation of oral drug bioavailability: From preclinical mechanism to therapeutic application. Cancer Invest 23:443-464, 2005
19. Daw NC, Furman WL, Stewart CF, et al: Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol 23:6172-6180, 2005
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
21. Owens TS, Dodds H, Fricke K, et al: Highperformance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 788:65-74, 2003
22. NONMEM Project Group UoCaSF: NONMEM Users' Guide Part I-VIII. San Francisco, CA, NONMEM Project Group, University of California at San Francisco, 1998
23. Bomgaars L, Kerr J, Berg S, et al: A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer 46:50-55, 2006
24. Vassal G, Doz F, Frappaz D, et al: A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 21:3844-3852, 2003
25. Blaney S, Berg SL, Pratt C, et al: A phase I study of irinotecan in pediatric patients: A pediatric oncology group study. Clin Cancer Res 7:32-37, 2001
26. Mugishima H, Matsunaga T, Yagi K, et al: Phase I study of irinotecan in pediatric patients with malignant solid tumors. J Pediatr Hematol Oncol 24:94-100, 2002
27. Houghton PJ, Cheshire PJ, Hallman JD, et al: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36: 393-403, 1995
28. Kruijtzer CM, Beijnen JH, Rosing H, et al: Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20: 2943-2950, 2002
29. Wagner LM, Crews KR, Iacono LC, et al: Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 10:840-848, 2004